

浏览全部资源
扫码关注微信
1.中国药科大学 药学院,南京 211198
2.天士力医药集团股份有限公司研究院 现代中药开发中心,天津 300410
3.天士力医药集团股份有限公司 创新中药关键技术国家重点实验室,天津 300410
4.天津大学 药物科学与技术学院,天津 300072
5.天津中医药大学 中药学院,天津 301617
Received:05 November 2021,
Published Online:22 February 2022,
Published:20 April 2022
移动端阅览
王云丹,张依倩,郝磊等.芪苓温肾消囊方化学成分及其治疗多囊卵巢综合征的作用机制分析[J].中国实验方剂学杂志,2022,28(08):183-193.
WANG Yun-dan,ZHANG Yi-qian,HAO Lei,et al.Chemical Components and Mechanism of Qiling Wenshen Formula in Treating Polycystic Ovary Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(08):183-193.
王云丹,张依倩,郝磊等.芪苓温肾消囊方化学成分及其治疗多囊卵巢综合征的作用机制分析[J].中国实验方剂学杂志,2022,28(08):183-193. DOI: 10.13422/j.cnki.syfjx.20220516.
WANG Yun-dan,ZHANG Yi-qian,HAO Lei,et al.Chemical Components and Mechanism of Qiling Wenshen Formula in Treating Polycystic Ovary Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(08):183-193. DOI: 10.13422/j.cnki.syfjx.20220516.
目的
2
系统分析芪苓温肾消囊方(QLWS)方的化学成分,探讨该方治疗多囊卵巢综合征(PCOS)的关键活性成分及作用机制。
方法
2
结合对照品比对和文献及数据库,采用超高效液相色谱-四级杆-飞行时间串联质谱法(UPLC-Q-TOF/MS
E
)对QLWS方化学成分进行系统分析与鉴定。采用中药系统药理学数据库和分析平台(TCMSP)及SwissADME平台筛选活性成分并进行网络药理学分析。通过SwissTargetPrediction、GeneCards、疾病相关基因与突变位点数据库(DisGeNET)、DrugBank等数据库获取该方治疗PCOS的潜在成分及靶点。借助STRING数据库构建蛋白质-蛋白质相互作用(PPI)网络筛选核心靶点。利用DAVID数据库对核心靶点进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。运用MOE 2019进行分子对接。
结果
2
从QLWS方中鉴定成分90个,经筛选得到32个活性成分和45个核心靶点。GO功能富集分析共得到429个条目,KEGG通路富集分析共得到110个条目,主要涉及磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/Akt)信号通路、雌激素信号通路、缺氧诱导因子-1(HIF-1)信号通路等。分子对接结果显示QLWS方中的关键活性成分淫羊藿苷、丹酚酸A/B/C、汉黄芩素、木兰花碱等可能通过调节促分裂原活化的蛋白激酶1(MAPK1)、表皮生长因子受体(EGFR)、促分裂原活化的蛋白激酶3(MAPK3)等靶点发挥治疗PCOS的作用。
结论
2
该研究基于液质联用技术及网络药理学技术初步预测了QLWS方中多个活性成分通过作用于多靶点、多通路治疗PCOS,为阐明全方的药效物质基础及作用机制研究提供思路与参考。
Objective
2
To systematically analyze the chemical components of QiLing Wenshen (QLWS) formula and explore the key active components and mechanism of the formula in the treatment of polycystic ovary syndrome (PCOS).
Method
2
The chemical components of QLWS formula were systematically identified by ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS
E
) combined with comparison with reference substances, literature data, and databases. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and SwissADME were employed to screen the active components for network pharmacological analysis. SwissTargetPrediction, GeneCards, DisGeNET, and DrugBank were used to obtain the potential components and targets of the formula for the treatment of PCOS. The protein-protein interaction (PPI) network was constructed via STRING database for further screening of the core targets. Gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of core targets were carried out with DAVID database. Molecular docking was performed in MOE 2019.
Result
2
A total of 90 components of QLWS formula were identified, and 32 active components and 45 core targets for treating PCOS were obtained. GO annotation obtained 429 terms and KEGG pathway enrichment screened out 110 signaling pathways, mainly involving phosphatidylin-ositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, estrogen signaling pathway, and hypoxia inducible factor-1 (HIF-1) signaling pathway. The molecular docking revealed that key active components in QLWS formula were icariin, salvianolic acid A\B\C, wogonin, magnoflorine, etc., which may play a role in treating PCOS through regulating mitogen-activated protein kinase 1 (MAPK1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 3 (MAPK3), etc.
Conclusion
2
This study preliminarily predicted that several key active components of QLWS formula could treat PCOS via multiple targets and multiple pathways based on UPLC-Q-TOF/MS
E
and network pharmacology, which could provide ideas and references for the study of pharmacodynamic material basis and mechanism of action of the formula.
YU J , YU C Q , CAO Q , et al . Consensus on the integrated traditional Chinese and Western medicine criteria of diagnostic classification in polycystic ovary syndrome (draft) [J]. J Integr Med , 2017 , 15 ( 2 ): 102 - 109 .
袁莹莹 , 赵君利 . 多囊卵巢综合征流行病学特点 [J]. 中国实用妇科与产科杂志 , 2019 , 35 ( 3 ): 261 - 264 .
HAYDEN B J , BALEN A H . The role of the central nervous system in the pathogenesis of polycystic ovary syndrome [J]. Minerva Ginecol , 2006 , 58 ( 1 ): 41 - 54 .
YANG Y , QIAO J , LI M . Study on the correlation between low-grade chronic inflammation and pathogenesis of polycystic ovary syndrome [J]. Fertil Steril , 2007 , 88 ( S1 ): S58 - S58 .
ZHU J , WITTEMANS L B L , LINDGREN C , et al . A genetically defined male counterpart of polycystic ovary syndrome:evidence for ovarian-independent pathogenesis [J]. J Endocr Soc , 2021 , 5 ( Suppl 1 ): A773 - A774 .
李玉婷 . 多囊卵巢综合征患者糖脂代谢的临床研究 [D]. 广州 : 南方医科大学 , 2013 .
EBRAHIMI F , ROSTAMI S , NEKOONAM S , et al . The effect of astaxanthin and metformin on oxidative stress in granulosa cells of BALB C mouse model of polycystic ovary syndrome [J]. Reprod Sci , 2021 , 28 ( 10 ): 2807 - 2815 .
中华医学会妇产科学分会内分泌学组及指南专家组 . 多囊卵巢综合征中国诊疗指南 [J]. 中华妇产科杂志 , 2018 , 53 ( 1 ): 2 - 6 .
辛俊英 . 多囊卵巢综合征药物治疗的研究进展 [J]. 当代医学 , 2012 , 18 ( 31 ): 17 - 19 .
ROCCA M L , VENTURELLA R , MOCCIARO R , et al . Polycystic ovary syndrome:chemical pharmacotherapy [J]. Expert Opin Pharmacother , 2015 , 16 ( 9 ): 1369 - 1393 .
刘宇新 , 侯丽辉 , 吴效科 . 多囊卵巢综合征中医病因病机 [J]. 天津中医药 , 2009 , 26 ( 2 ): 123 - 124 .
张阳 , 凌娜 , 张国华 , 等 . 基于深度学习多囊卵巢综合征辨证分型的构建与实现 [J]. 辽宁中医药大学学报 , 2019 , 21 ( 5 ): 13 - 16 .
侯阿美 , 储继军 . 基于数据挖掘的中医药治疗多囊卵巢综合征的用药规律分析 [J]. 西南医科大学学报 , 2021 , 44 ( 4 ): 392 - 398 .
孟家宁 , 王昕 . 补肾化痰法治疗多囊卵巢综合征研究进展 [J]. 实用中医内科杂志 , 2020 , 34 ( 11 ): 18 - 22 .
侯丽辉 , 王晓冰 , 吴效科 . 从"痰壅胞宫"病机理论论多囊卵巢综合征排卵障碍 [J]. 中国中医基础医学杂志 , 2008 , 14 ( 10 ): 725 - 726 .
王波 , 侯丽辉 , 吴效科 ." 天癸失序,痰壅胞宫"——PCOS生殖藏象病理探析 [J]. 世界中西医结合杂志 , 2009 , 4 ( 11 ): 768 - 771 .
杨新鸣 , 王淑言 , 邹红 , 等 . 多囊卵巢综合征"痰壅胞宫"的形态学特征 [J]. 中医药信息 , 2011 , 28 ( 5 ): 26 - 29 .
鲁彩霞 . 补肾化痰方治疗痰湿型多囊卵巢综合征临床和代谢组学研究 [D]. 哈尔滨 : 黑龙江中医药大学 , 2014 .
任那 , 刘翠翠 , 侯丽辉 . 穴位埋线联合补肾化痰方治疗痰湿内盛型肥胖的疗效观察 [J]. 中医药学报 , 2020 , 48 ( 2 ): 54 - 58 .
尹倩 , 侯丽辉 , 刘颖华 , 等 . 补肾化痰方对多囊卵巢综合征患者高雄激素血症影响的临床观察 [J]. 上海中医药杂志 , 2015 , 49 ( 8 ): 53 - 55,70 .
鲁彩霞 , 苑程鲲 , 侯丽辉 . 补肾化痰方治疗胰岛素抵抗PCOS的临床研究 [J]. 中医药学报 , 2015 , 43 ( 6 ): 58 - 61 .
牛静云 , 侯丽辉 , 李妍 , 等 . 补肾活血方治疗肾虚血瘀型多囊卵巢综合征闭经患者的效果 [J]. 中国医药导报 , 2017 , 14 ( 23 ): 175 - 178 .
尹倩 , 侯丽辉 , 葛军 , 等 . 补肾化痰方对肥胖型多囊卵巢综合征不孕患者子宫内膜容受性的影响 [J]. 世界中西医结合杂志 , 2015 , 10 ( 11 ): 1541 - 1544,1558 .
DAINA A , MICHIELIN O , ZOETE V . SwissTargetPrediction:updated data and new features for efficient prediction of protein targets of small molecules [J]. Nucleic Acids Res , 2019 , 47 ( W1 ): W357 - W364 .
XU Y , PAN C S , LI Q , et al . The ameliorating effects of Bushen Huatan granules and Kunling Wan on polycystic ovary syndrome induced by dehydroepiandrosterone in rats [J]. Front Physiol , 2021 , 12 : 525145 .
孙宁宁 , 张可佳 , 耿婉丽 , 等 . 基于UPLC-Q-TOF-MS的加参片提取物化学成分分析 [J]. 中草药 , 2018 , 49 ( 2 ): 293 - 304 .
周洁 , 汤维维 , 陈君 . 基于UPLC-QTOF-MS/MS法的茅苍术与北苍术化学成分分析 [J]. 药学与临床研究 , 2020 , 28 ( 5 ): 321 - 328 .
于雪娥 , 秦建平 , 李家春 , 等 . 基于UPLC/Q-TOF-MS/MS技术快速分析淫羊藿总黄酮胶囊中的化学成分 [J]. 中国中药杂志 , 2016 , 41 ( 24 ): 4587 - 4597 .
马文娟 , 姚广哲 , 贾琪 , 等 . UPLC-Q-TOF-MS/MS法定性分析淫羊藿中的化学成分 [J]. 中药材 , 2019 , 42 ( 7 ): 1554 - 1559 .
王媛 , 袁磊 , 李遇伯 , 等 . 基于UPLC-Q-TOF-MS的淫羊藿化学成分分析 [J]. 中草药 , 2017 , 48 ( 13 ): 2625 - 2631 .
陈嘉慧 , 张雅心 , 刘孟华 , 等 . 基于UPLC-Q-TOF-MS/MS技术的丹参水提液全成分分析 [J]. 广东药科大学学报 , 2020 , 36 ( 1 ): 1 - 9 .
甘井山 , 马艳 , 王宗艳 , 等 . 淫羊藿中化学成分的UPLC/Q-TOF-MS分析 [J]. 现代药物与临床 , 2014 , 29 ( 4 ): 349 - 352 .
LIU A H , GUO H , YE M , et al . Detection,characterization and identification of phenolic acids in Danshen using high-performance liquid chromatography with diode array detection and electrospray ionization mass spectrometry [J]. J Chromatogr A , 2007 , 1161 ( 1/2 ): 170 - 182 .
LI W , POLACHI N , WANG X , et al . A quality marker study on salvianolic acids for injection [J]. Phytomedicine , 2018 , 44 : 138 - 147 .
芮雯 , 冯毅凡 , 石忠峰 , 等 . 不同产地黄芪药材的UPLC/Q-TOF-MS指纹图谱研究 [J]. 药物分析杂志 , 2012 , 32 ( 4 ): 607 - 611,642 .
信悦 , 白晶 . 复方黄芪生脉饮化学成分的UPLC-Q-TOF/MS分析 [J]. 哈尔滨商业大学学报:自然科学版 , 2021 , 37 ( 1 ): 21 - 25,78 .
ZHAO H Y , SUN J H , FAN M X , et al . Analysis of phenolic compounds in Epimedium plants using liquid chromatography coupled with electrospray ionization mass spectrometry [J]. J Chromatogr A , 2008 , 1190 ( 1/2 ): 157 - 181 .
邓桃妹 , 彭代银 , 俞年军 , 等 . 茯苓化学成分和药理作用研究进展及质量标志物的预测分析 [J]. 中草药 , 2020 , 51 ( 10 ): 2703 - 2717 .
徐彩生 , 罗丽莉 , 曾如辉 , 等 . 淫羊藿总黄酮对多囊卵巢综合征大鼠性激素水平的影响 [J]. 重庆医科大学学报 , 2013 , 38 ( 2 ): 147 - 150 .
李美玲 . 淫羊藿苷通过调节卵巢颗粒细胞增殖与分泌功能改善DOR患者IVF助孕结局的临床与机制研究 [D]. 南京 : 南京中医药大学 , 2020 .
LIANG Y , XIE L , LIU K , et al . Bergapten:A review of its pharmacology,pharmacokinetics,and toxicity [J]. Phytother Res , 2021 , 35 ( 11 ): 6131 - 6147 .
李佳川 . 基于本草知识的酒蒸黄连“止消渴”系统研究 [D]. 成都 : 成都中医药大学 , 2011 .
孙玲 . 木兰花碱对LPS诱导的急性肺损伤的保护作用探讨 [J]. 世界最新医学信息文摘(连续型电子期刊) , 2019 , 19 ( 29 ): 100 - 101 .
任晓东 , 符伟 , 张晓芸 , 等 . 天然产物汉黄芩素的研究进展 [J]. 中国新药杂志 , 2011 , 20 ( 9 ): 777 - 784 .
戈升荣 , 俞一心 , 谢更新 . 丹酚酸的药理作用研究进展 [J]. 中药材 , 2002 , 25 ( 9 ): 683 - 686 .
XIAO Z , LIU W , MU Y P , et al . Pharmacological effects of salvianolic acid b against oxidative damage [J]. Front Pharmacol , 2020 , 11 : 572373 .
黄鸣清 . 丹酚酸B改善2型糖尿病大鼠IR作用及其机制研究 [D]. 广州 : 广州中医药大学 , 2010 .
翁静 . EGF与生殖 [J]. 首都医科大学学报 , 2001 , 22 ( 1 ): 91 - 93 .
马会明 , 黑常春 , 张永芳 , 等 . EGF通过PI3K/Akt通路介导小鼠卵巢颗粒细胞增殖 [J]. 宁夏医科大学学报 , 2014 , 36 ( 5 ): 483 - 486,490 .
MOHAMMADI S , KAYEDPOOR P , KARIMZADEH-BARDEI L , et al . The effect of curcumin on TNF- α ,IL-6 and CRP expression in a model of polycystic ovary syndrome as an inflammation state [J]. J Reprod Infertil , 2017 , 18 ( 4 ): 352 - 360 .
BAO L , SYED R , ALOAHD M S . Analysis of VEGF gene polymorphisms and serum VEGF protein levels contribution in polycystic ovary syndrome of patients [J]. Mol Biol Rep , 2019 , 46 ( 6 ): 5821 - 5829 .
LIU H Y , HUANG Y L , LIU J Q , et al . Transcription factor‑microRNA synergistic regulatory network revealing the mechanism of polycystic ovary syndrome [J]. Mol Med Rep , 2016 , 13 ( 5 ): 3920 - 3928 .
MEHDINEJADIANI S , AMIDI F , MEHDIZADEH M , et al . Effects of letrozole and clomiphene citrate on Wnt signaling pathway in endometrium of polycystic ovarian syndrome and healthy women [J]. Biol Reprod , 2019 , 100 ( 3 ): 641 - 648 .
KHALILZADEH B , SHADJOU N , KANBEROGLU G S , et al . Advances in nanomaterial based optical biosensing and bioimaging of apoptosis via Caspase-3 activity:a review [J]. Mikrochim Acta , 2018 , 185 ( 9 ): 434 .
VILLAVICENCIO A , GOYENECHE A , TELLERIA C , et al . Involvement of Akt,Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome [J]. Gynecol Oncol , 2009 , 115 ( 1 ): 102 - 107 .
洪艳丽 , 吴飞 . 补肾化痰方对多囊卵巢综合征胰岛素抵抗Akt通路调控的实验研究 [J]. 中国中西医结合杂志 , 2014 , 34 ( 2 ): 230 - 234 .
WANG F , ZHANG Z , WANG Z , et al . Expression and clinical significance of the HIF-1a/ET-2 signaling pathway during the development and treatment of polycystic ovary syndrome [J]. J Mol Histol , 2015 , 46 ( 2 ): 173 - 181 .
TANG Z R , ZHANG R , LIAN Z X , et al . Estrogen-receptor expression and function in female reproductive disease [J]. Cells , 2019 , 8 ( 10 ): 1123 .
许爱霞 , 郑莉萍 , 唐丹凤 , 等 . MAPK/PKC信号通路在原癌基因c-erbB 2 调控原始卵泡启动生长中的作用 [J]. 生理学报 , 2009 , 61 ( 5 ): 439 - 444 .
0
Views
26
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621